A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Recruiting · NCT06322667 · Observational (researchers observe without assigning treatment) · Lead sponsor: Eisai Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
No Intervention
What this trial is about
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- All participants who are treated with lecanemab in routine clinical practice
Exclusion criteria
- None
Where it is running
3 locations listed.
- Eisai trial site 2 - Hiroshima, Japan
- Eisai trial site 3 - Kyoto, Japan
- Eisai trial site 1 - Tokyo, Japan